12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ICT-107: Phase IIb amended

ImmunoCellular amended a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating ICT-107 in 231 newly diagnosed GBM patients to increase enrollment in a subset of patients who are major histocompatibility...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >